Stephen Silverstein, DO
Internal Medicine · Pompano Beach, FLNPI 1326026568
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 82.7% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $1,682 and has fallen 98.6% since, to $24 in 2024.
Across 73 payments — averaging $41.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Boehringer Ingelheim$105
- Novo Nordisk$88
- GSK$76
- AbbVie$59
- Lilly USA, LLC$57
- plus $141 from 7 others
What the payments were for
- Food & beverage$3,037100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 45 | $2,511 |
| Boehringer Ingelheim | 6 | $105 |
| Novo Nordisk | 5 | $88 |
| GSK | 4 | $76 |
| AbbVie | 1 | $59 |
| Lilly USA, LLC | 4 | $57 |
| Novartis | 2 | $32 |
| Saluda Medical Americas, Inc. | 1 | $24 |
| Amgen | 1 | $22 |
| Pfizer | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,037 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 73 | $60,464 |
| GlyxambiEmpagliflozin/Linagliptin | 72 | $53,877 |
| EliquisApixaban | 57 | $43,674 |
| XareltoRivaroxaban | 54 | $43,037 |
| JanuviaSitagliptin Phosphate | 25 | $20,431 |
| EntrestoSacubitril/Valsartan | 20 | $15,810 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 11 | $15,093 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 23 | $14,951 |
| OzempicSemaglutide | 12 | $13,218 |
| TrulicityDulaglutide | 12 | $11,440 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $9,374 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 316 | $8,068 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,891 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $7,428 |
| Repatha PushtronexEvolocumab | 12 | $7,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr | $105 | $129,292168 claims |
| PfizerEliquis | $20 | $43,67457 claims |
| Johnson & JohnsonXarelto | $2,511 | $43,03754 claims |
| NovartisEntresto | $32 | $15,81020 claims |
| Novo NordiskOzempic | $88 | $13,21812 claims |
| Lilly USA, LLCTrulicity | $57 | $11,44012 claims |
| AstraZenecaBreztri Aerosphere | $12 | $7,89112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Pompano Beach
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.